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Volume 54, Number 6 Abstracts 1847surgical group were associated with incompetence of the below knee GSV.
Perhaps length of GSV stripping should more reflect the length of the
refluxing vein and not concerns about injuring the saphenous nerve? An-
other interesting point is that neovasculariztion, thought to be the leading
cause of recurrence of varicosities in patients with traditional open surgical
treatment of GSV varicosities, appears rare after EVLA. The reason for this is
unclear, but may be due to decreased inflammation following EVLA.
Interestingly, all patients with recanalization after EVLA in this trial, were
treated with an energy density of 60 J/cm. No recanaliztion was seen when
energy densities were above 115 J/cm.
Comparative Predictors of Mortality for Endovascular and Open Re-
pair of Ruptured Infrarenal Abdominal Aortic Aneurysms
Sarac TP, Bannazadeh M, Rowan AF, et al. Ann Vasc Surg 2011;25:461-8.
Conclusion:Mortality rates for EVAR treatment and open treatment
of ruptured aortic aneurysm are equal with regard to 30 day and long term
mortality.
Summary: Many patients with ruptured abdominal aortic aneurysm
(rAAA) die before reaching surgery (Acosta S. J Vasc Surg 2006;44:237-
43). In-hospital mortality rates range between 30 and 70%. A large meta
analysis found an overall 48% mortality (Brown MJ Br J Surg 2002;89:714-
30). EVAR for rAAA was first described in 1994 (Marin ML et al. Ann Surg
1995;222:449-65) and is gaining in popularity. The authors sought to
evaluate their results of treatment of rAAA with a particular focus in
comparing endovascular repair of rAAA versus open surgery repair. Between
January of 1990 and May of 2008 there were 160 patients who underwent
repair of rAAA. Twenty percent (n  32) underwent EVAR for rAAA. 112
were felt to have free rupture (70%) and 48 a contained rupture (30%).
Average acute physiology and chronic health evaluation II score was 13.3
6.7. Survival at 30 days, 6 months, 1 year and 5 years was 69%, 57%, 50% and
25%. There were no differences seen in the EVAR group compared to the
open surgical group (P .24). There was 5.6 % intraoperative mortality. No
patient undergoing EVAR suffered intraoperative death (P  .03). Thirty-
day mortality for EVAR was 31.2% and was 32% for open surgery (P .93).
Renal insufficiency (OR, 2.4; 1.1-5.3; P  .04), hypotension (OR, 2.4;
1.1-5.3; P  .02) and cardiac arrest (OR, 3.8; 1.1-11.6; P  .03) were all
associated with increased mortality. The only independent predictor of
decreased long term survival was preoperative renal insufficiency (OR, 2.32;
1.55-3.47; P  .001).
Comment: There is clearly a trend towards increasing use of EVAR for
treatment of rAAA and most clinician’s clinical impression is that outcomes
are better. This study however showed equal morality with open and
endovascular repair of rAAA. The series is retrospective with different
surgeons over time. We don’t know the precise selection criteria for the two
procedures and there may be unmeasured confounding variables. What we
can really say from this paper is that despite the use of EVAR for repair for
rAAA, mortality remains high. EVAR is clearly a viable option for treatment
of rAAA. Despite many surgeon’s clinical impression, whether EVAR, when
applicable, truly reduces mortality of rAAA in equal patients, compared to
open repair, has not been conclusively proven to everyone’s satisfaction.
Effect of Hypoxia-Inducible Factor-1 Gene Therapy on Walking
Performance in Patients With Intermittent Claudication
Creager MA, Olin JW, Belch JJ, et al. Circulation 2011;124:1765-73.
Conclusion:Gene therapy with intramuscular administration of Ad2/
HIF-1/VP16 is not effective treatment for intermittent claudication.
Summary: Induction of angiogenesis of lower extremity arteries via
protein, gene based, or cellular therapy may result in new blood vessel
formation and improved blood flow in patients with intermittent claudica-
tion. Hypoxia- inducible factor 1 (HIF-1) is a transcriptional regulatory
factor with important roles in cellular response to changes in oxygen tension
(Semenza GL. Science 2007; 318:62-4). HIF-1 exerts control on multiple
genes providing adaptive responses to hypoxia at the cellular level. HIF-1/
V16 is hybrid transcription factor comprised of a truncated HIF-1 se-
quence fused to a herpes simplex virus (VP16) transactivator. A previous
phase 1 trial of patients with critical limb ischemia indicated that Ad2/HIF-
1/VP16, an engineered recombinant type 2 adenovirus vector encoding
active HIF-1, provided resolution of rest pain and ulcer healing (Rajago-
palan S et al. Circulation 2007;115:1234-43). The authors postulated
intramuscular administration of Ad2/HIF-1/VP16 could improve peak
walking time (PWT) in patients with intermittent claudication. This was a
randomized double blind prospective study where 289 patients with claudi-
tion were randomized to one of three doses of Ad2/HIF-1/VP16 (2x10 9,
2  10 10, or 2  10 11 viral particles) or placebo. Medications were
administered with 20 intramuscular injections to each leg. Graded treadmill
exercise tests were performed at baseline, and at 3, 6 and 12 months after
treatment. The primary endpoint was a change in PWT from baseline to 6
months, and the secondary endpoint was a change in claudition onset time.
Tertiary endpoints included changes in ankle-brachial index and quality of
life assessments.
B
bMedian PWT increase by 0.82 minutes (interquartile range, 0.05-
.93 minutes) in the placebo group and increased by 0.82 minutes (inter-
uartile range, 0.07-2.12 minutes ), 0.28 minutes (interquartile range,
0.37-1.7 minutes), and 0.78 minutes(interquartile range, 0.02-2.10
inutes) in the HIF-1 2  10 9, 2  10 10 2  10 11 viral particle groups
espectively (P  NS for all comparisons). There were no significant differ-
nces in claudication onset time, ankle-brachial index or quality of life
easurements between the placebo group and each of the HIF-1 groups.
here were no dramatic safety differences between the placebo groups and
he HIF-1 groups.
Comment: HIF-1 may be ineffective inducing angiogenesis. How-
ver, there are other possible reasons the study failed to prove efficacy of
IF-1 for treatment of intermittent claudication. There may differences in
iologic activity of HIF-1 in patients with claudication compared to critical
imb ischemia. Adenovirus transfection may not be efficient in skeletal
uscle. Duration of gene expression may be to short for development and
aintenance of collateral vessels. The distance between injection sites may
ave been too great to enable efficient collateral development. Finally,
espite attempts to mitigate the placebo response, patients randomized to
lacebo increased peak walking distance by approximately 30%. This study
hould be regarded as negative under the conditions employed in the study.
ellular and gene based therapies still remain intriguing possibilities in the
reatment of PAD.However, it is going to be time consuming and expensive
o prove they are not just intriguing but also effective.
ystematic Review and Meta-Analysis of Growth Rates of Small Ab-
ominal Aortic Aneurysms
owell JT, Sweeting MJ, Brown LC et al. Br J Surg 2011;98:609-18.
Conclusion: In studies reporting growth rates of small abdominal
ortic aneurysms (AAA) there is considerable variation in growth rate,
eyond that which can be explained by aneurysm diameter alone.
Summary: Many institutions and countries have adopted policies for
creening for AAA in older men. However, there is relatively little informa-
ion on optimal surveillance protocols in patients where an AAA has been
dentified but does not currently meet criteria for repair. Observational
tudies have also reported growth rates of small AAAs with disparate recom-
endations for follow up examinations of AAAs that do not meet threshold
riteria for repair. Other clinically relevant questions include whether AAA
rowth rate is faster in smokers, slower in patients with diabetes, and
hether there are any gender differences in growth rates. Based on these
onsiderations, the authors thought to synthesize the published data on
rowth rates of small AAA in a systematic review to provide an evidence basis
or surveillance intervals.
The review consisted of literature published prior to January 2010.
here were 61 potentially eligible reports identified. Review of these reports
ielded 15 studies providing growth rates for aneurysms between 3.0-5.5
entimeters in diameter. These 15 studies included 7630 individuals (pre-
ominately men) who were enrolled between 1976 and 2005. The review
ndicated the pooled growth rate for AAA was 2.32 mm per year (95% CI,
.95 to 2.7 mm/year). There was high heterogeneity between studies with
rowth rates ranging from 0.33 mm/year to 3.95 mm/year. There was a
rend for growth rates to increase with aneurysm diameter. A 10 mm
ncrease in aneurysm diameter was associated with a mean (s.e.m.) 1.62
0.20) mm/year increase in growth rate. Percentage of women in studies
nd mean age did not have a significant effect on growth rate. Medical
herapies, smoking, and co-morbidities were inconsistently reported in the
5 studies and their influence on growth rates could not be evaluated. On
verage, the data indicate a 3.5 cm aneurysm will take 6.2 years to reach 5.5
m. A 4.5-cm aneurysm will reach 5.5 cm in about 2.3 years.
Comment:This study provides evidence growth rates of AAAs increase
ith aneurysm diameter. However, it did not completely satisfy the primary
oal to determine optimal surveillance intervals because of the marked
eterogeneity of growth rates in individual studies. Whereas the data would
ndicate that larger aneurysms grow faster than smaller aneurysms, some-
hingmost of us already suspected, it does not provide useful information on
he influence of patient characteristics, including age, sex smoking, diabetes
nd other relevant factors on AAA growth rates that would help optimize
ecommendations for surveillance intervals.
he von Willebrand Inhibitor ARC1779 Reduces Cerebral Emboliza-
ion After Carotid Endarterectomy a Randomized Trial
arkus HS, McCollum C, Imray C, et al. Stroke 2011;42:2149-53.
Conclusion: von Willebrand factor inhibition reduces thromboembo-
ism and may play a role in treatment of stroke and myocardial ischemia.
Summary:Minor stroke and transient ischemic attacks are followed by
high early risk of recurrent stroke. Risk is highest in patients with larger
rtery disease. Aspirin can reduce recurrent stroke, but actually fails to
revent 80% of stroke recurrences (Antithrombotic Trialists’ Collaboratio.
MJ 2002;324:71-86). There are now novel antiplatelet therapies that may
e considered. It appears inhibition of platelet receptor glycoprotein (GPIb)
